Cel-Sci Corporation (NYSEAMERICAN:CVM) Sees Large Increase in Short Interest

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 522,417 shares, an increase of 28.5% from the January 15th total of 406,465 shares. Approximately 7.2% of the company’s shares are sold short. Based on an average trading volume of 102,730 shares, the days-to-cover ratio is presently 5.1 days. Based on an average trading volume of 102,730 shares, the days-to-cover ratio is presently 5.1 days. Approximately 7.2% of the company’s shares are sold short.

Institutional Investors Weigh In On Cel-Sci

A number of hedge funds have recently bought and sold shares of CVM. Vanguard Group Inc. lifted its position in shares of Cel-Sci by 59.7% during the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after buying an additional 109,352 shares during the last quarter. Geode Capital Management LLC raised its stake in Cel-Sci by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock worth $417,000 after acquiring an additional 18,432 shares in the last quarter. MAI Capital Management lifted its position in Cel-Sci by 18.4% in the third quarter. MAI Capital Management now owns 76,861 shares of the company’s stock valued at $707,000 after acquiring an additional 11,928 shares during the last quarter. Bank of America Corp DE boosted its stake in Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after acquiring an additional 39,190 shares in the last quarter. Finally, State Street Corp boosted its stake in Cel-Sci by 9.9% in the fourth quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after acquiring an additional 2,300 shares in the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

Cel-Sci Price Performance

Shares of CVM opened at $4.78 on Wednesday. The company has a market cap of $40.20 million, a P/E ratio of -0.49 and a beta of 0.77. Cel-Sci has a fifty-two week low of $1.98 and a fifty-two week high of $20.41. The company has a quick ratio of 2.20, a current ratio of 2.26 and a debt-to-equity ratio of 0.36. The firm’s 50 day moving average price is $5.40 and its 200 day moving average price is $7.49.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Tuesday, December 23rd. The company reported ($0.76) EPS for the quarter. On average, research analysts forecast that Cel-Sci will post -0.29 earnings per share for the current fiscal year.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.